P2RY12 and coronary artery disorder: Moreover, the far majority of participants included in the randomized trials of double therapy (OAC plus P2Y12 inhibitor) or triple therapy (OAC plus dual antiplatelet therapy) in the setting of AF and percutaneous coronary intervention (PCI) for coronary artery disease received clopidogrel instead of one of the more potent P2Y12 inhibitors.15–18 As a result, contemporary guidelines recommend clopidogrel as the P2Y12 inhibitor of choice in patients with AF and ACS treated with PCI.12